Licensing Partner of Shenzhen Chipscreen Biosciences – HUYABIO International, Receives Regulatory Approval for Chidamide Monotherapy of Adult T-cell Leukemia/lymphoma in Japan

SHENZHEN, China, June 24, 2021 /PRNewswire/ -- Shenzhen Chipscreen Biosciences' licensing partner, HUYABIO International (HUYABIO™), today announced the regulatory approval for Tucidinostat (also known as Chidamid...

Full "IntellAsia: Resources" article